Care-path focus
On the Launchpad contract
Livozo is the brand and marketing site only. Clinical decisions, if any, sit with independent partner clinicians — never with Livozo.
Longevity · Launchpad care path
NAD+ (NAD) is on the OpenLoop Launchpad contract. Livozo is the brand and marketing site; after a qualify CTA, OpenLoop hosts intake and their clinicians decide whether NAD+ is appropriate. Compounded NAD+ is not FDA-approved. Care is not live until Launchpad is wired.
At a glance
Care-path focus
Livozo is the brand and marketing site only. Clinical decisions, if any, sit with independent partner clinicians — never with Livozo.
Care-path focus
Livozo is the brand and marketing site only. Clinical decisions, if any, sit with independent partner clinicians — never with Livozo.
Care-path focus
Livozo is the brand and marketing site only. Clinical decisions, if any, sit with independent partner clinicians — never with Livozo.
Clinical context
These pages describe possible pathways, not a promise that any medication will be prescribed, shipped this week, or available in any state today. Livozo does not employ the prescriber.
Partner model
Exact medication, formulation, quantity, refill timing, and pharmacy routing depend on the clinical partner, applicable law, and clinical appropriateness. OpenLoop's licensed 503A network — not an exclusive Red Rock claim — fulfills partner prescriptions if written.
Next step
This is a Launchpad care path, not live clinician care. A “see if I qualify” step is meant to hand off to OpenLoop white-label intake when that contract is wired. Until then, eligibility is informational. No prescription, charge, or shipment happens from this site.
See if I qualify